Buy & Sell Annaly Capital Management, Inc. (NLY) – Annaly Capital Management, Inc. Price Today
Aura AI Summary
Key Stats
- $16.44BMarket Cap
- FinancialsSector
- -10.78%3M Drawdown
- -Enterprise Value
- 12.48%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 91 daysTypical Hold Time
Annaly Capital Management, Inc. (NLY) is currently valued at a market capitalization of $16.44B. Over the past 52 weeks, Annaly Capital Management, Inc. has traded between a low of $18.69 and a high of $24.4, highlighting its annual price range. Over the past three months, Annaly Capital Management, Inc. has recorded a drawdown of -10.78%, reflecting recent price volatility. Annaly Capital Management, Inc. offers a dividend yield of 12.48%, with the most recent dividend of $0.70 paid on 31 Mar 26. On average, investors hold Annaly Capital Management, Inc. for approximately 91 days, indicating typical investor behavior on the platform.
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Most Recent News
Investec Bank discloses share dealings in Advanced Medical Solutions Group on May 11, 2026
Investec Bank plc, acting as advisor and joint broker to Advanced Medical Solutions Group plc, disclosed its share dealings on May 11, 2026. The bank purchased 269,588 ordinary shares at prices between 252.5 and 255 pence and sold 241,501 shares at p...
Rigel Pharmaceuticals inks deal with Arvinas and Pfizer for breast cancer drug VEPPANU, shares jump 10.7%.
Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and Pfizer to develop and commercialize VEPPANU, an oral PROTAC drug for advanced breast cancer. The FDA recently approved VEPPANU for estrogen receptor-positive, ...
AI stocks plunge as broad profit-taking hits semiconductors, cloud, and tech ETFs after Jim Cramer's reversal warning.
AI-related stocks, especially in semiconductors, cloud infrastructure, and tech ETFs, saw sharp declines following a warning from CNBC host Jim Cramer about a potential market reversal. The sell-off was broad, reflecting profit-taking in a crowded AI...
